Corvus Pharmaceuticals Inc
SWB:C17
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Corvus Pharmaceuticals Inc (C17) under the Base Case is 3.34 EUR per share.
Compared with the current market price of 10.09 EUR, the stock appears
Overvalued by 67% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Corvus Pharmaceuticals Does
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that tries to turn lab discoveries into new medicines for immune-related diseases and cancer. It does not sell a broad line of approved drugs. Instead, it advances a small group of drug candidates through preclinical work and clinical trials to see whether they are safe and effective enough for approval.
- Headquarters
- United States of America US
- Employees
- 29
- IPO date
- Mar 23, 2016
Revenue & Expenses Breakdown
Corvus Pharmaceuticals Inc
Earnings Waterfall
Corvus Pharmaceuticals Inc
Continue C17 Research
Decided on Corvus Pharmaceuticals? Get an email when C17 reaches the price you’d buy at. Free with an account.
Other Corvus Pharmaceuticals listings
What is the Intrinsic Value of one C17 stock?
The intrinsic value for Corvus Pharmaceuticals Inc (C17) under the Base Case is 3.34 EUR.
Is C17 stock undervalued or overvalued?
Compared with the current market price of 10.09 EUR, the stock appears Overvalued by 67% .
